Regulus Therapeutics Inc (NASDAQ: RGLS) is 77.22% higher on its value in year-to-date trading and has touched a low of $0.83 and a high of $2.90 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RGLS stock was last observed hovering at around $2.55 in the last trading session, with the day’s gains setting it 0.25%.
Currently trading at $2.80, the stock is 46.89% and 79.71% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.85 million and changing 9.80% at the moment leaves the stock 82.04% off its SMA200. RGLS registered 27.27% gain for a year compared to 6-month loss of 86.67%. The firm has a 50-day simple moving average (SMA 50) of $1.5582 and a 200-day simple moving average (SMA200) of $1.5382.
The stock witnessed a 115.38% gain in the last 1 month and extending the period to 3 months gives it a 131.40%, and is 44.33% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.23% over the week and 14.01% over the month.
Regulus Therapeutics Inc (RGLS) has around 34 employees, a market worth around $185.48M and $0.00M in sales. Distance from 52-week low is 237.31% and -3.45% from its 52-week high. The company has generated returns on investments over the last 12 months (-60.45%).
The EPS is expected to shrink by -42.89% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
91.0 institutions hold shares in Regulus Therapeutics Inc (RGLS), with institutional investors hold 88.63% of the company’s shares. The shares outstanding are 65.50M, and float is at 53.18M with Short Float at 5.00%. Institutions hold 86.69% of the Float.
The top institutional shareholder in the company is FEDERATED HERMES, INC. with over 12.85 million shares valued at $22.94 million. The investor’s holdings represent 19.9374 of the RGLS Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 6.25 million shares valued at $11.16 million to account for 9.6952 of the shares outstanding. The other top investors are VIVO CAPITAL, LLC which holds 5.0 million shares representing 7.7561 and valued at over $8.93 million, while OCTAGON CAPITAL ADVISORS LP holds 6.614 of the shares totaling 4.26 million with a market value of $7.61 million.
Regulus Therapeutics Inc (RGLS) Insider Activity
The most recent transaction is an insider purchase by Hagan Joseph P, the company’s Chief Executive Officer. SEC filings show that Hagan Joseph P bought 50,000 shares of the company’s common stock on Jan 30 ’25 at a price of $1.09 per share for a total of $54260.0. Following the purchase, the insider now owns 0.26 million shares.
Regulus Therapeutics Inc disclosed in a document filed with the SEC on Jan 30 ’25 that BALTIMORE DAVID (Director) bought a total of 19,610 shares of the company’s common stock. The trade occurred on Jan 30 ’25 and was made at $1.06 per share for $20787.0. Following the transaction, the insider now directly holds 22169.0 shares of the RGLS stock.
Still, SEC filings show that on Jan 13 ’25, Aker Christopher Ray (Sr. VP & General Counsel) disposed off 38,547 shares at an average price of $1.26 for $48693.0. The insider now directly holds 54,634 shares of Regulus Therapeutics Inc (RGLS).
